Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$38.00

0.62 (1.66%)

, PFE

Pfizer

$41.98

0.45 (1.08%)

14:15
06/03/19
06/03
14:15
06/03/19
14:15

AstraZeneca plans to launch search for next chairman, Sky News says

AstraZeneca (AZN) is preparing to launch a search for a successor to chairman Leif Johansson, who has chaired the company for seven years and helped it fend off Pfizer's (PFE) takeover bid five years ago, Sky News' Mark Kleinman reports. Sources close to AstraZeneca told Kleinman that there was official timetable in place yet for Johansson's departure, but suggested that the company's nomination and governance committee was beginning to consider the issue more formally. Reference Link

AZN

AstraZeneca

$38.00

0.62 (1.66%)

PFE

Pfizer

$41.98

0.45 (1.08%)

  • 03

    Jun

  • 06

    Jun

  • 20

    Jun

AZN AstraZeneca
$38.00

0.62 (1.66%)

05/29/19
HCWC
05/29/19
NO CHANGE
HCWC
Buy
AstraZeneca decision does not impact MEDI0457, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju says AstraZeneca's (AZN) decision to discontinue activities related to two new DNA-based cancer vaccine candidates from Inovio (INO) does not affect MEDI0457. AstraZeneca continues to pursue the development of MEDI0457, which is being evaluated in combination with durvalumab in multiple Phase 2 studies in HPV-related cancers, Selvaraju tells investors in a research note. Inovio is eligible to receive up to $700M potential milestone payments, including $250M related to MEDI0457, says the analyst. He reiterates a Buy rating on Inovio with a $13 price target.
05/29/19
CANT
05/29/19
NO CHANGE
Target $12
CANT
Overweight
Inovio milestones from Astra still worth up to $250M, says Cantor Fitzgerald
Inovio (INO) announced that it received notification from MedImmune, a subsidiary of AstraZeneca (AZN), that it plans to discontinue research collaboration programs except for the MEDI0457/ durvalumab combo studies that are in multiple Phase 2 trials in patients with HPV associated cancers, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. Despite "strained optics," the collaboration change makes sense, says the analyst. He estimates Inovio's MEDI0457 milestones are worth up to $250M and keeps an Overweight rating on the shares with a $12 price target.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
05/30/19
SBSH
05/30/19
NO CHANGE
Target $7
SBSH
Buy
Inovio risk/reward attractive into data readouts, says Citi
Citi analyst Joel Beatty lowered his price target for Inovio Pharmaceuticals (INO) to $7 from $10 after AstraZeneca (AZN) decided to discontinue activities with respect to its rights to co-develop up to two new DNA-based cancer vaccine product candidates. The analyst, however, says this is a good time to buy shares of Inovio. The company has three phase 1/2 immuno-oncology combo trials expected to readout in the second half of 2019, and the stock's risk/reward is attractive into the news, Beatty tells investors in a research note.
PFE Pfizer
$41.98

0.45 (1.08%)

05/28/19
PIPR
05/28/19
NO CHANGE
PIPR
Piper more bullish on GlycoMimetics, Global Blood into upcoming catalysts
After surveying 25 sickle cell disease experts, Piper Jaffray analyst Danielle Brill is "incrementally more bullish" on both GlycoMimetics (GLYC) and Global Blood Therapeutics (GBT) into their upcoming catalysts. GlycoMimetics and partner Pfizer (PFE) have pivotal Phase 3 results with rivipansel, their pan-selectin inhibitor, reading out in July, Brill tells investors in a research note. And Global Blood Therapeutics is expected to complete its new drug application submission for voxelotor via the accelerated approval pathway and present full Phase 3 Hope trial data in June, adds the analyst. Following expert feedback, Brill remains confident for a successful Phase 3 outcome with rivipansel. She believes positive data will drive GlycoMimetics shares "meaningfully higher" in July. Further, the majority of the surveyed doctors believe voxelotor's hemolytic anemia benefit is clinically relevant and most expect accelerated approval based on these data, adds the analyst.
05/28/19
GSCO
05/28/19
INITIATION
Target $49
GSCO
Conviction Buy
Pfizer initiated with a Conviction Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Pfizer with a Buy rating and added the shares to his firm's Americas Conviction List. He has a $49 price target for the shares. Flynn expects Pfizer's growth to inflect in 2021 with revenue of $57.4B, ahead of the $56B consensus estimate. He also projects the company's operating margins will expand from 38.1% in 2019 to 40.6% in 2022 as revenue growth outpaces expenses.
05/29/19
CANT
05/29/19
NO CHANGE
Target $53
CANT
Overweight
Pfizer sales potential Vyndaqel/Vyndamax underappreciated, says Cantor
Cantor Fitzgerald analyst Louise Chen says her "quick poll" of cardiologists supports the view that the peak sales potential of Pfizer's Vyndaqel/Vyndamax is underappreciated. The sales could be "meaningfully higher" than the 2024 consensus forecasts of $1.5B given a treatment cost of $225,000 per patient per year and a potential treatment population of 1M-plus in the U.S., Chen tells investors in a research note. She thinks the growing usage of scintigraphy for diagnosing transthyretin amyloid cardiomyopathy will increase the number of patients that are identified and eligible for treatment. The analyst reiterates an Overweight rating on Pfizer with a $53 price target.

TODAY'S FREE FLY STORIES

STRM

Streamline Health

$1.20

0.02 (1.69%)

, AGO

Assured Guaranty

$47.16

0.28 (0.60%)

13:19
10/21/19
10/21
13:19
10/21/19
13:19
On The Fly
Fly Insider: Streamline, Proofpoint among week's notable insider trades »

Welcome to "Fly Insider,"…

STRM

Streamline Health

$1.20

0.02 (1.69%)

AGO

Assured Guaranty

$47.16

0.28 (0.60%)

TAYD

Taylor Devices

$10.72

0.21 (2.00%)

CMCT

CIM Commercial Trust

$14.70

0.1 (0.68%)

ATNX

Athenex

$9.81

-0.39 (-3.82%)

OKTA

Okta

$101.00

2.32 (2.35%)

LRCX

Lam Research

$239.22

5.56 (2.38%)

FISV

Fiserv

$104.30

-1.41 (-1.33%)

PFPT

Proofpoint

$120.13

0.7 (0.59%)

ANET

Arista Networks

$245.27

5.57 (2.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 31

    Oct

  • 05

    Nov

  • 05

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Dec

  • 12

    Dec

  • 16

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
10/21/19
10/21
13:17
10/21/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
10/21/19
10/21
13:16
10/21/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRM

Iron Mountain

$33.96

0.44 (1.31%)

13:15
10/21/19
10/21
13:15
10/21/19
13:15
Options
Iron Mountain put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 12

    Nov

BA

Boeing

$333.70

-10.39 (-3.02%)

13:05
10/21/19
10/21
13:05
10/21/19
13:05
Periodicals
Boeing CEO cites 'steady progress' on 737 MAX in internal email, Reuters says »

Boeing's CEO said in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FTCH

Farfetch

$8.18

0.15 (1.87%)

13:05
10/21/19
10/21
13:05
10/21/19
13:05
Options
Farfetch Limited call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$299.80

1.815 (0.61%)

13:04
10/21/19
10/21
13:04
10/21/19
13:04
Periodicals
POTUS says trade pact with China coming along great, Reuters says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$299.80

1.815 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$118.45

0.96 (0.82%)

, MCD

McDonald's

$209.91

1.43 (0.69%)

13:03
10/21/19
10/21
13:03
10/21/19
13:03
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$118.45

0.96 (0.82%)

MCD

McDonald's

$209.91

1.43 (0.69%)

UTX

United Technologies

$138.27

1.42 (1.04%)

NEE

NextEra Energy

$231.47

-1.21 (-0.52%)

LMT

Lockheed Martin

$373.98

1.36 (0.36%)

UPS

UPS

$119.05

1.72 (1.47%)

SHW

Sherwin-Williams

$559.43

-1.54 (-0.27%)

KMB

Kimberly-Clark

$138.03

0.73 (0.53%)

BIIB

Biogen

$224.66

4.61 (2.10%)

TRV

Travelers

$141.76

0.32 (0.23%)

PCAR

Paccar

$73.44

1.39 (1.93%)

FITB

Fifth Third

$27.91

0.575 (2.10%)

CNC

Centene

$46.98

0.06 (0.13%)

RF

Regions Financial

$16.08

0.3 (1.90%)

NUE

Nucor

$52.25

0.56 (1.08%)

HAS

Hasbro

$120.60

-1.29 (-1.06%)

TRU

TransUnion

$82.01

0.52 (0.64%)

DGX

Quest Diagnostics

$102.55

-0.12 (-0.12%)

IPG

Interpublic Group

$20.69

0.04 (0.19%)

HOG

Harley-Davidson

$37.11

0.53 (1.45%)

PII

Polaris Industries

$92.01

1.395 (1.54%)

SNV

Synovus

$36.36

1.07 (3.03%)

JBLU

JetBlue

$17.63

0.675 (3.98%)

GPK

Graphic Packaging

$15.01

0.355 (2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 07

    Nov

  • 10

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 04

    Dec

  • 07

    Dec

BMRN

BioMarin

$68.98

-0.18 (-0.26%)

13:03
10/21/19
10/21
13:03
10/21/19
13:03
Hot Stocks
BioMarin treatment of phenylketonuria granted FDA orphan status »

BioMarin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 07

    Dec

UPS

UPS

$119.07

1.74 (1.48%)

, FDX

FedEx

$153.86

3.97 (2.65%)

13:00
10/21/19
10/21
13:00
10/21/19
13:00
Earnings
Fly Intel: What to watch in UPS earnings report »

UPS (UPS) is scheduled to…

UPS

UPS

$119.07

1.74 (1.48%)

FDX

FedEx

$153.86

3.97 (2.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 13

    Nov

  • 17

    Dec

AMTD

TD Ameritrade

$37.85

1.06 (2.88%)

, CDNS

Cadence Design

$66.73

1.13 (1.72%)

12:59
10/21/19
10/21
12:59
10/21/19
12:59
Earnings
Notable companies reporting after market close »

Notable companies…

AMTD

TD Ameritrade

$37.85

1.06 (2.88%)

CDNS

Cadence Design

$66.73

1.13 (1.72%)

CE

Celanese

$122.11

0.44 (0.36%)

ZION

Zions Bancorp

$45.40

0.68 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 06

    Nov

  • 19

    Nov

EL

Estee Lauder

$186.09

0.44 (0.24%)

12:56
10/21/19
10/21
12:56
10/21/19
12:56
Downgrade
Estee Lauder rating change  »

Estee Lauder downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 31

    Oct

  • 15

    Nov

12:50
10/21/19
10/21
12:50
10/21/19
12:50
General news
Treasury's agenda for the November refunding meeting wanted dealer insights »

Treasury's agenda…

FB

Facebook

$189.22

3.265 (1.76%)

12:49
10/21/19
10/21
12:49
10/21/19
12:49
Hot Stocks
Facebook updates inauthentic behavior policy to counter new tactics »

Facebook said in a post…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

FB

Facebook

$189.22

3.265 (1.76%)

12:48
10/21/19
10/21
12:48
10/21/19
12:48
Hot Stocks
Facebook launches 'Protect' to secure accounts of elected officials »

Facebook announced on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

OPOF

Old Point Financial

$24.61

(0.00%)

12:46
10/21/19
10/21
12:46
10/21/19
12:46
Hot Stocks
Old Point Financial appoints Elizabeth Beale CFO »

Elizabeth Beale has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOS

Mosaic

$19.72

0.16 (0.82%)

12:45
10/21/19
10/21
12:45
10/21/19
12:45
Options
Mosaic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 13

    Nov

INFO

IHS Markit

$69.67

-0.08 (-0.11%)

12:41
10/21/19
10/21
12:41
10/21/19
12:41
Conference/Events
IHS Markit management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

MSFT

Microsoft

$137.79

0.45 (0.33%)

12:36
10/21/19
10/21
12:36
10/21/19
12:36
Hot Stocks
Microsoft acquires cloud file migration provider Mover; terms not disclosed »

Jeff Teper, CVP Office,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 21

    Nov

DEST

Destination Maternity

$0.20

-0.136 (-40.48%)

12:27
10/21/19
10/21
12:27
10/21/19
12:27
Periodicals
Destination Maternity plans bankruptcy filing in next few weeks, CNBC reports »

Destination Maternity is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$39.14

0.305 (0.79%)

12:25
10/21/19
10/21
12:25
10/21/19
12:25
Options
PagSeguro Digital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

  • 17

    Dec

GSK

GlaxoSmithKline

$42.46

-0.06 (-0.14%)

12:20
10/21/19
10/21
12:20
10/21/19
12:20
Hot Stocks
GlaxoSmithKline to divest rabies, tick-borne encephalitis vaccines »

GlaxoSmithKline announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 30

    Oct

  • 07

    Dec

12:20
10/21/19
10/21
12:20
10/21/19
12:20
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
10/21/19
10/21
12:17
10/21/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$330.78

-13.31 (-3.87%)

, ABC

AmerisourceBergen

$86.00

-3.67 (-4.09%)

12:16
10/21/19
10/21
12:16
10/21/19
12:16
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have been higher…

BA

Boeing

$330.78

-13.31 (-3.87%)

ABC

AmerisourceBergen

$86.00

-3.67 (-4.09%)

CAH

Cardinal Health

$50.02

-1.62 (-3.14%)

MCK

McKesson

$145.20

-7.29 (-4.78%)

TEVA

Teva

$7.67

0.17 (2.27%)

IPHS

Innophos Holdings

$31.97

-3.39 (-9.59%)

SGEN

Seattle Genetics

$101.10

13.68 (15.65%)

PETS

PetMed Express

$24.60

5.15 (26.48%)

INFY

Infosys

$9.20

-1.37 (-12.96%)

MFGP

Micro Focus

$13.25

-1.88 (-12.43%)

OTEX

OpenText

$40.00

0.7 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 11

    Nov

  • 19

    Nov

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.